Special Issue "Advances in the Molecular Basis of BRCA-Associated Cancers"
Deadline for manuscript submissions: 22 December 2021.
Interests: breast cancer; cancer genetics and genomics; cancer risk assessment; molecular epidemiology
Special Issues and Collections in MDPI journals
BRCA1 and BRCA2 (BRCA) are tumor suppressor genes, encoding proteins involved in homologous recombination DNA repair pathways. Inherited mutations in BRCA genes are well known for their predisposition to the hereditary breast and ovarian cancer syndrome in women, but they have also been observed in association with additional types of cancers, including male breast, prostate, pancreatic, and melanoma.
Next-generation sequencing technology affords an unprecedented opportunity to analyze BRCA genes in a cost-effective way, allowing for the analysis of a large number of cancer patients, but, on the other hand, it poses challenges in the functional interpretation of the higher number of variants of unknown significance that are identified.
To date, key clinical improvements have been derived from the identification of peculiar tumor molecular subtypes associated with BRCA mutational status, e.g., triple-negative breast cancers, which are characterized by their aggressive behavior.
Personalized therapeutic strategies in BRCA-associated tumors, such as the use of PARP inhibitors, have proved very promising and have been incorporated into the clinical setting.
This Special Issue will focus on the molecular biology of BRCA genes, the functional evaluation of BRCA variants, genotype–phenotype correlations, the molecular profiling of BRCA-associated tumors, BRCA interactors in DNA repair, synthetic lethality, and other possible therapeutic mechanisms. Original research articles, reviews, and short communications related to these topics are welcomed.
Dr. Valentina Silvestri
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- hereditary cancers
- cancer genetics
- molecular mechanisms of pathogenicity
- genotype–phenotype correlation
- tumor profiling
- germline and somatic variant testing